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A method has been developed for rapid and sensitive identification of epitope-containing
peptides, based on direct MALDI-MS/MS analysis of epitope-containing peptides affinity
bound to affinity beads. This technique provides sequence information of the epitope that
allows unambiguous identification of the epitope either by database searching or de novo
sequencing. With MALDI-MS, affinity beads with bound peptides can be placed directly on
the MALDI target and analyzed. Coupling a MALDI source to an orthogonal injection
quadrupole time-of-flight (QqTOF) mass spectrometer allows direct sequencing of the bound
peptides. In contrast to ESI-MS/MS, elution of the affinity-bound peptides followed by
additional concentration and purification steps is not required, thus reducing the potential for
sample loss. Direct mass spectrometric sequencing of affinity-bound peptides eliminates the
need for chemical or enzymatic sequencing. Other advantages of this direct MALDI-MS/MS
analysis of epitope-containing peptides bound to the affinity beads include its sensitivity
(femtomole levels) and speed. In addition, direct analysis of peptides on affinity beads does
not adversely affect the high mass accuracy of a QqTOF, and database searching can be
performed on the MS/MS spectra obtained. In proof-of-principle experiments, this method has
been demonstrated on beads containing immobilized antibodies against phosphotyrosine, the
c-myc epitope tag, as well as immobilized avidin. Furthermore, de novo sequencing of
epitope-containing peptides is demonstrated. The first application of this method was with
anti-FLAG-tag affinity beads, where direct MALDI MS/MS was used to determine an
unexpected enzymatic cleavage site on a growth factor protein. (J Am Soc Mass Spectrom
2003, 14, 1076–1085) © 2003 American Society for Mass Spectrometry
The determination of the amino acid sequence ofepitope-containing peptides is of major interest inbroad areas of biochemical and biomedical re-
search. Information about the epitope and eventual
cross-reactivity of the antibody is very important for
quality assurance of antibodies, especially when these
antibodies are to be used in diagnostic and protein chip
technologies. In addition, knowledge about the epitope-
containing sequence also can provide crucial informa-
tion for elucidating autoimmune diseases, as well as for
proteomics and protein characterization studies. Some
methods advocated for these studies utilize affinity
chromatography techniques for isolating the epitope-
containing peptide(s). Identification of the affinity-iso-
lated peptides can lead directly to identification of the
protein and can also provide information on the loca-
tion of modification sites, including phosphorylation
sites.
For identification of epitope-containing peptides,
mass spectrometry (MS) is advantageous because of its
inherent speed, sensitivity, and its capability of se-
quencing peptides, compared to conventional methods
[1, 2]. Antibodies are immobilized on agarose beads,
and are used for immunoprecipitation of epitope-con-
taining peptides. Traditionally, solution-phase separa-
tions such as high performance liquid chromatography
(HPLC) coupled to mass spectrometry or ionization
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techniques such as nano-electrospray mass spectro-
metry (nESI-MS) have been used to identify the epitope-
containing peptides. It is necessary, however, to elute
the peptides from the beads prior to the analysis step,
introducing the potential for sample loss. With matrix-
assisted laser desorption/ionization mass spectrometry
(MALDI-MS) analysis, it is possible to perform
MALDI-MS of affinity-bound peptides or proteins by
spotting an aliquot of affinity beads directly onto the
MALDI target, without prior elution.
It has been demonstrated for immobilized metal ion
affinity chromatography (IMAC) [3], that the MALDI
matrix solvent may actually strip the affinity-bound
peptides or proteins off the beads during cocrystalliza-
tion with the matrix. However, the term “direct”
MALDI analysis is used for techniques where the
affinity beads are placed directly on the target, to
contrast this method with “indirect” methods involving
separate and time-consuming purification/elution
steps (with concomitant losses due to sample handling)
prior to spotting the eluate on the target.
Until recently, only protein molecular weight infor-
mation and peptide mass fingerprinting data could be
obtained by direct MALDI-MS of affinity-bound ana-
lytes [4–6]. To obtain sequence information on a par-
ticular affinity-bound peptide, enzymatic sequencing
experiments had to be performed while the peptides
were still bound to the beads [4, 7, 8]. While this has
proven to be a useful approach for epitope mapping
and other applications [6, 8, 9–11], the resulting data
can be difficult to interpret if more than one peptide is
isolated, or if several residues are cleaved simulta-
neously.
With the coupling of a MALDI source to quadru-
pole/time-of-flight instruments (QqTOF) [12, 13], se-
quencing can now be performed directly in the gas
phase, via collision-induced dissociation (CID) with
tandem mass spectrometry (MS/MS). The additional
mass selection offers the advantages of directly obtain-
ing sequence information from each peptide in a rapid
manner, without interference from other bound pep-
tides. Direct MALDI-MS/MS of phosphorylated pep-
tides bound to IMAC beads on a QqTOF has previously
been reported [14]. The work presented here extends
the direct MALDI-MS/MS approach to sequence
epitope-containing peptides bound to a variety of anti-
body beads. In contrast to earlier reports on MALDI-
TOF instruments [4, 15], no loss of mass accuracy
results from analyzing the affinity beads directly on the
target. The data presented in this paper demonstrate
that based on the high mass accuracy obtained with a
QqTOF, database searching, and de novo sequencing
for protein identification can be successfully performed
on the MS/MS spectra obtained, even with only femto-
moles of peptide present. Thus, the direct MALDI-
MS/MS approach for affinity-bound peptides is well




The kinase domain of the insulin receptor peptide (KDIR)
(Thr-Arg-Asp-Ile-Tyr-Glu-Thr-Asp-Tyr-Tyr-Arg-Lys), the
phosphorylated kinase domain of the insulin receptor
peptide no. 3 (pKDIR) (Thr-Arg-Asp-Ile-Tyr-Glu-Thr-
Asp-Tyr-pTyr-Arg-Lys), and the biotinylated kinase do-
main of the insulin receptor peptide (biotinKDIR) (Biotin-
Thr-Arg-Asp-Ile-Tyr-Glu-Thr-Asp-Tyr-Tyr-Arg-Lys) were
purchased from AnaSpec (San Jose, CA). The c-myc
peptide (Cys-Glu-Gln-Lys-Leu-Ile-Ser-Glu-Glu-Asp-Leu)
was purchased from Covance (Berkeley, CA). Standard
TGF-FLAG peptide (Val-Val-Ala-Ala-Ser-Gln-Lys-Lys-Gln-
Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys-Val-Val) has been
described previously [16]. All peptides were used without
further purification. Stock solutions were prepared at a
concentration of 1 g/L in HPLC-grade water, and
serially diluted with HPLC-grade water.
Immobilized antiphosphotyrosine antibody, avidin
agarose, and monoclonal anti-FLAG M2 affinity resin
beads were purchased from Sigma Chemical Co., and
anti-myc 9E10 affinity beads were purchased from Co-
vance (Berkeley, CA).
Methods
Affinity binding for the standard peptides was carried
out in compact reaction columns (CRCs) (USB Corpo-
ration, Cleveland, OH). A typical column volume for a
standard was 10 L. The beads were washed with 1.5
mL of 1 phosphate-buffered saline (PBS) prior to
incubation. The peptides were then incubated with the
beads for 2 h, in an Eppendorf Thermomixer at 400 rpm,
at 25 °C. For each standard, a series of different loadings
(2 to 700 pmol) was incubated with the beads. After
incubation, the beads were washed with 1.5 mL of 1
PBS. The beads were never allowed to dry out.
Details of the TACE (tumor necrosis factor- con-
verting enzyme) digestion, and isolation of FLAG-
tagged peptides are described elsewhere [16]. Briefly,
the medium concentrate solution was incubated with
1 g recombinant human TACE extracellular domain
[17] at 37 °C for 4 h, and reactions were stopped by
addition of EDTA to 10 mM final concentration. Prod-
ucts containing the FLAG epitope were immunopre-
cipitated by overnight incubation with anti-FLAG M2
affinity resin in 50 mM Tris pH 7.4, 150 mM NaCl. The
beads were washed five times with 50 mM ammonium
bicarbonate, and a 0.5 L aliquot of the settled beads
was spotted on the MALDI target.
Mass Spectrometry
MALDI/TOF-MS was performed on a Bruker Instru-
ments Co. (Billerica, MA) Reflex III, with pulsed ion
extraction. MALDI-MS and MALDI-MS/MS were per-
formed on an Applied Biosystems Div. Perkin-Elmer
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Corp. (Foster City, CA) API QSTAR-Pulsar (QSTAR),
with argon as the collision gas. The instrument is
equipped with a nitrogen laser operating at 337 nm.
For experiments on the Reflex III, recrystallized
-cyano-4-hydroxycinnamic acid (HCCA) (Aldrich,
Milwaukee, WI) was used as the matrix. The solvent for
HCCA was 45:45:10 ethanol:water:formic acid, and
used as a saturated solution. A premixed matrix solu-
tion containing 2,5-dihydrobenzoic acid (DHB) (Agilent
Technologies Inc., Palo Alto, CA) was used without
further dilution for experiments on the QSTAR. A 0.5
L aliquot of the settled beads was spotted on the
target, followed by 0.5 L matrix solution, and the
solution was allowed to dry at room temperature.
Calculation of the Amount of Peptide on the
MALDI Target
Exactly determining the amount of affinity-bound pep-
tide applied to the MALDI target is difficult. The bed
volume of the affinity beads is 10 L, and 1/20 of the
bed volume is spotted on the MALDI target. However,
the entire 0.5 L volume is not solely composed of
beads. Between 800-1000 beads are present in 10 L of
beads. However, often only 15–30 beads were present
on the MALDI target. Therefore, dividing the amount of
peptide incubated with the beads by 25 (800 beads
incubated divided by 30 beads on target) provides a
maximum amount on the MALDI target. Practically, the
amount of peptide is most likely much less than what
was calculated. This is due to variations in the amount
of beads used for immunoprecipitation, as well as the
number of beads applied to the MALDI target. For
example, if 1000 beads were used for immunoprecipi-
tation, and only 15 were applied to the MALDI target,
only 1.5% of the original peptide solution is present for
MS analysis.
Database Searching
For searching and interpreting MALDI-MS/MS spectra,
Mascot software [18] was used. Searches considered
only the Homo sapiens genome, and a mass accuracy of
100 ppm in the precursor ion mass and 0.1 Da in the
product ion masses was entered. When applicable, a
fixed modification of “Biotin (N-term)” or a variable
modification of “Phospho (S,T) and Phospho (Y)” was
entered. The nomenclature of Roepstorff and Fohlman
[19], later modified by Biemann [20], was used to
identify all product ions.
Results and Discussion
Proof-of-Principle Experiments
To evaluate the method of direct MALDI-MS/MS se-
quencing of epitope-containing peptides bound to af-
finity beads in regards to sensitivity, mass accuracy,
and protein identification via database searching and de
novo sequencing, model peptides bound to beads con-
taining immobilized anti-phosphotyrosine antibodies,
anti-c-myc antibodies and immobilized avidin were
analyzed.
Phosphotyrosine/Anti-Phosphotyrosine Binding
Phosphorylated pKDIR peptide at several concentra-
tions was incubated with an antibody against phos-
phorylated tyrosine, immobilized on agarose beads. As
can be seen in Figure 1a, with a maximum of 234 fmol
of affinity-bound peptide loaded on the target, the
protonated molecule ([M  H]) at m/z 1702.553 of the
phosphorylated peptide was observed, with a signal to
noise ratio (S/N) greater than 10, as well as a loss of 98
Da (m/z 1604.477), corresponding to loss of H3PO4, of
approximately 25% relative intensity. The resolution
obtained for the peak at m/z 1702.553 was 11,601. The
ability of the antibody to completely capture all phos-
phorylated peptides was examined, by performing
MALDI-MS of the pass-through. As shown in Figure 1b,
no ion signal is observed at m/z 1702.5, indicating that
the antibody beads have selectively bound all phos-
phorylated peptide present in the solution.
The MALDI-MS/MS spectrum of m/z 1702.553 is
shown in Figure 1c depicting several b and y ions. The
six most abundant product ions from the MALDI-
MS/MS spectrum were submitted to Mascot for data-
base searching. Because this peptide does not corre-
spond to an enzymatic fragment, no enzyme was
specified in the search. Even without any enzyme
restriction the insulin receptor protein, along with sev-
eral homologous proteins, was identified as the top hit,
with an average error of 106 ppm in the product ions
masses (Note: This mass accuracy could be achieved
even from ion signals with S/N  3). Several proteins
were identified as the top hit because each protein
sequence contains the KDIR peptide. This demonstrates
that analyzing peptides affinity-bound to antibody
beads does not compromise the mass accuracy of the
QqTOF. The ability to search MS/MS spectra, with high
mass accuracy, is crucial for the unambiguous identifi-
cation of peptides [21] and especially for the identifica-
tion of phosphorylation sites. High mass accuracy is
even more critical for this method, since only one
peptide, the epitope-containing peptide, is available for
protein identification.
This method is not only well suited for testing the
specificity of the antibody, as shown in the previous
section, but also for testing the selectivity of the anti-
body. Thus, a mixture of the same KDIR peptide, in
both its phosphorylated and its unphosphorylated
form, (Figure 2a), was incubated with another aliquot of
the antibody beads. For accurate comparison, the same
amount of peptide as that shown in Figure 1a was
applied to the beads. As can be seen in Figure 2b, none
of the unphosphorylated sequence was captured by the
antibody, indicating that it is highly specific for phos-
phorylated tyrosine residues.
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This has important implications for proteomics, as it
demonstrates that anti-phosphotyrosine beads can be
used to both isolate and concentrate phosphorylated
peptide(s) of interest from a complex mixture. Our
previous work with binding this peptide on IMAC
beads [14] allows a comparison of the two methods.
Using the Fe(III)-IMAC beads, not all of the peptide was
removed from the solution, and a significant peptide
signal was obtained from MALDI/MS analysis of the
pass-through (data not shown). This implies that anti-
phosphotyrosine beads have an advantage over IMAC
beads for trapping low levels of phosphopeptide. Un-
fortunately, however, this advantage only holds for
phosphotyrosine-containing phosphopeptides. The
binding of serine and threonine phosphopeptides to
immobilized anti-phosphoserine and phosphothreo-
nine beads was less successful, and no selectivity was
found for phosphoserine and phosphothreonine-con-
taining peptides over their corresponding non-phos-
phorylated analogues (data not shown). It has been
reported that commercially-available antibodies against
phosphoserine and phosphothreonine are not sufficient
for use in immunoprecipitation [22]. Thus, for peptides
phosphorylated on serine or threonine, the IMAC tech-
nique would be preferable.
Myc/Anti-Myc Binding
Several concentrations of a standard peptide containing
the c-myc epitope, from the human c-myc gene, were
incubated with agarose beads containing an immobi-
Figure 1. (a) shows the MALDI-MS spectrum of the pKDIR
peptide bound to antibody beads. A maximum of 234 fmol is
present on the MALDI target. (b) shows the MALDI-MS spectrum
of the pass-through, indicating complete capture of the phosphor-
ylated peptide. (c) is the MALDI-MS/MS spectrum of the ion at
m/z 1702.
Figure 2. (a) shows the MALDI-MS spectrum of the starting
material, an equimolar mixture of phosphorylated and unphos-
phorylated KDIR peptide. (b) shows the MALDI-MS spectrum of
an aliquot of the antibody beads after incubation, indicating that
only the phosphorylated sequence has been captured.
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lized antibody against the c-myc epitope (EQKLI-
SEEDL). A representative MALDI-MS spectrum is
shown in Figure 3a. Although the solution incubated
with the affinity beads was supposed to contain only a
single peptide sequence, it was apparent from the
MALDI-MS spectrum that two peptides containing the
c-myc epitope were present, at m/z 1306.493 and
1458.464. A MALDI-MS spectrum of the control anti-c-
myc antibody beads confirmed that there was no con-
tamination from the beads at m/z 1458.464 (data not
shown).
MALDI-MS/MS spectra of these peptides affinity-
bound to the antibody beads are shown in Figure 3b
and c. To determine the complete peptide sequence, a
slightly higher loading (a maximum of 3.1 pmol) was
applied to the sample target, to increase the number of
sequence-specific ions that would be observed. A com-
plete b ion series, from b2 to b10, was observed for the
expected sequence, at m/z 1306.493. Because this pep-
tide is a synthetic construct, and not present in a protein
sequence, this MALDI-MS/MS spectrum was not sub-
mitted for database searching. The human myc proto-
oncogene protein (accession no. P01106) has a Glu
residue (Glu416) preceding the epitope tag, instead of a
Cys. FASTA (http://www.ebi.ac.uk/fasta33/) was
used to search for homologous proteins, and the c-myc
proto-oncogene protein was unambiguously identified.
The average mass error observed in these experiments
was 85 ppm.
For the unexpected peptide detected in the synthetic
standard, de novo sequencing was necessary to identify
the amino acid sequence of the peptide. A series of ions,
differing in mass by 128 Da was observed, which
identified the first four residues of this peptide as Gln,
and the fifth residue as Lys. With the high mass
accuracy of the QqTOF, Lys (128.094 Da) and Gln
(128.059 Da) can be differentiated, even though there is
only a 0.04 Da difference. The remaining residues were
identical in sequence to the expected peptide. A com-
plete b ion series, from b1 to b7 was observed, as well as
the b9 and b11 ions. Due to the b8 and b10 ions not being
observed, amino acid pairs were determined from the
mass differences measured between the b7 and b9 ions,
as well as the b9 and b11 ions.
This c-myc study emphasizes the importance of being
able to rapidly perform MS/MS sequencing of affinity-
bound peptides. Although the c-myc epitope has been
reported to be (EQKLISEEDL), the peptide at m/z
1458.464 only has a portion of this epitope tag
(QKLISEEDL), yet was still immunoprecipitated by the
anti-c-myc antibody. Partial epitope recognition can
lead to cross-reactivity, and isolation of contaminating
proteins. It is crucial to be able to quickly identify all
proteins isolated by an antibody, especially for protein
chips using antibodies. Additionally, this direct
MALDI-MS/MS technique simplifies definition of an
unknown epitope. Like the previous direct MALDI-MS
approach [6], this direct MALDI-MS/MS method is
applicable both to the epitope extraction and the
epitope excision methodologies.
In the previous method [6], the epitope itself was not
sequenced — it stayed affinity bound to the antibody
until the MALDI-MS analysis step, and its intact molec-
ular weight was determined by direct MALDI-MS of
the affinity beads. Successive iterative enzymatic cleav-
Figure 3. Direct MALDI-MS and MS/MS of the anti-c-myc re-
sults. (a) shows the MALDI-MS spectrum of the affinity-captured
peptides. The peptide at m/z 1458.464 was unexpected. (b) shows
the MALDI-MS/MS spectrum of the ion at m/z 1306.493. (c) is the
MALDI-MS/MS spectrum of the ion at m/z 1458.464. Note that in
both MALDI-MS/MS spectra almost complete series of b ions was
observed.
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ages were performed on the affinity-bound intact anti-
body. This “ladder sequencing” [23] approach allowed
one to determine the sequence of the
non-epitopicportion of the epitope-containing peptide
(residues forming the actual epitope were protected by
the antibody and could not be enzymatically cleaved).
Enzymatic cleavages from both the N- and C-termini
allowed the epitope to be mapped by matching the
peptide molecular weight to what was left on the beads
after enzymatic cleavage of the non-epitopic portion of
the peptide. This approach relied on an antigenic pro-
tein with a known sequence.
The ability to sequence the epitope directly opens up
the possibility of shortening the process of epitope
mapping intact antigens. Getting an enzymatic “se-
quence tag” of the epitope-containing peptide is no
longer a requirement. Instead of a series of successive,
iterative, enzymatic digestions and MALDI analyses, it
should be possible to use a mix of enzymes and longer
digestion times. In this way, one could go directly to the
epitope and sequence it with MALDI-MS/MS. This
would allow epitope mapping of proteins whose se-
quence either is not known, or (as in HIV) where the
protein sequence is variable. It should also, in principle,
be possible to sequence epitopes from unknown pro-
teins, thus identifying both the epitope and the anti-
genic protein in a single step. One area where this might
be of use would be autoimmune diseases. In this case
the antibodies could be isolated and immobilized, and
their antigenic protein and the epitope could be deter-
mined by direct MS/MS analysis of the affinity beads.
This approach would also simplify epitope determi-
nation of polyclonal antibodies. While the direct
MALDI-MS approach has been demonstrated for a
polyclonal antibody with a known 14-residue epitope
region [24], all of the bound peptides were digested
simultaneously, and sorting out the results can be
confusing. (An analogy would be performing Edman
sequencing on a mixture of peptides.) This would be
very difficult on an unknown epitope. The direct
MALDI-MS/MS approach would allow direct sequenc-
ing of each of the affinity-bound peptides separately.
Another potential use of this approach is to charac-
terize discontinuous epitopes. In this case, however, the
binding to the affinity beads must be performed prior to
digestion to avoid structural impairment of the discontin-
uous epitope which might lead to loss of binding affinity
[25, 26]. In the event that the discontinuous epitope is too
high in mass for sequencing by MALDI-MS/MS, the use
of higher laser power and/or HCCA instead of DHB can
extend the accessible m/z range [27]. In addition, the
method of dual enzymatic digestion [28] can be used to
create smaller affinity-bound peptides with lower MW’s
amenable to direct sequencing by MALDI-MS/MS.
Biotin/Avidin Binding
The biotinKDIR peptide was incubated with agarose
beads containing an immobilized avidin moiety. Be-
cause the biotin avidin association is one of the stron-
gest non-covalent interactions, initially an aliquot of
beads containing a maximum of 2.16 pmol of affinity-
bound peptide was placed on the MALDI target, and
the MALDI-MS spectrum can be seen in Figure 4a.
Strong signal is observed for the protonated molecule
([MH]), with a S/N ratio greater than 30. MALDI-
MS/MS was performed on the ion at m/z 1848.743, and
the MALDI-MS/MS spectrum is shown in Figure 4b.
Several sequence-specific b and y ions were observed,
which were sufficient for identifying the peptide se-
quence.
With a lower sample loading (250 fmol loading),
MALDI-MS/MS spectra can still be obtained (Figure 5).
Although only four product ions are present with a S/N
greater than 2, the mass accuracy was high enough to
identify the protein by database searching, specifying a
fixed modification of N-terminal biotinylation. The in-
Figure 4. MALDI-MS and MALDI-MS/MS of biotinylated pep-
tide affinity-bound to immobilized avidin beads. (a) is the
MALDI-MS spectrum, with a maximum of 2.16 pmol on target. (b)
is the MALDI-MS/MS spectrum, with sequence-specific b and y
ions indicated.
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sulin receptor (accession no. NP_S000199), along with
several variants, was identified, with an average error
of 65 ppm in the product ion masses. It should be noted
that this MALDI-MS/MS spectrum was obtained with a
maximum of 216 fmol spotted on the target. Even with
mid-femtomole amounts of sample applied to the
MALDI target, the protein can unambiguously be iden-
tified via database searching.
Although the biotin-avidin association (Kd 
1015M) [29, 30] is stronger than the biotin-streptavidin
association, (Kd  10
13M) [31] the standard biotinyl-
ated peptide was easily dissociated from the avidin
agarose under MALDI conditions. Thus, even com-
pounds with high dissociation constants can still be
measured using direct MALDI-MS/MS of peptides
affinity-bound to antibody beads.
The sequence information obtained on the peptides
bound to the affinity beads is very useful for establish-
ing assays to characterize and quantify the binding
affinity of the bound peptide, for example, competitive
assays with a radioactive labeled derivative of the
bound peptide. Thus, the method described in this
manuscript makes it possible to obtain the ultimate
proof of specific binding.
Nelson and coworkers have performed MALDI/MS
analysis directly from BIAcore chips [32–35]. While
direct MALDI-MS/MS has not yet been used for the
direct analysis of peptides bound to BIAcore chips, the
technique described in this manuscript should be ap-
plicable to direct MALDI-MS/MS of peptides bound to
BIAcore chips as well as affinity beads, thus providing
sequence information without the necessity of eluting
and concentrating. The combined approach of BIAcore
and MALDI-MS/MS would be attractive because the
BIAcore technique provides information on the binding
affinity and kinetics which is not provided by MALDI-
MS/MS.
Are the Peptides Bound to the Antibody Beads?
There has been some speculation in the literature
whether or not the peptides are still bound to the beads
following the addition of matrix solution [3, 4]. Quite
recently, it was reported that the DHB matrix solvent
actually can “elute” the phosphorylated peptides from
IMAC beads during the spotting process [3]. To test
whether or not the peptides are similarly released from
antibody beads during the spotting process, a standard
peptide, bound to beads containing an immobilized
anti-FLAG antibody, was spotted with HCCA. Spectra
were acquired when beads were irradiated by the laser
(Figure 6a), and when only matrix crystals were being
irradiated by the laser (Figure 6b). Clearly some elution
is occurring, as strong signal is obtained when the laser
irradiates only matrix crystals. However, it is interest-
ing to note that there is greater signal intensity when the
beads are in the laser path, indicating that some peptide
may remain bound to, or closely associated with, the
antibody beads during the spotting process.
To determine if the acid or the organic solvent was
responsible for the release of the peptide from the
antibody beads, an aliquot of the beads was spotted
using only HCCA and methanol as the matrix solution.
The mass spectrum acquired with no beads in the laser
path (Figure 6c) indicates that very little peptide was
released from the beads. Therefore, it is the addition of
acid to the matrix solvent that promotes peptide release
from the antibody beads. It has been speculated that the
addition of acid to the peptide-antibody complex pro-
motes dissociation [2]. Regardless of whether the pep-
tides remain bound or are eluted, spotting the affinity
beads directly on the MALDI target allows detection of
mid-femtomole amounts of peptide, with the ability to
perform MS/MS analysis.
Application of the Method to Identify In Vitro
Proteolysis Products of TACE
First application of the method has been performed to
assess the ability of tumor necrosis factor- converting
enzyme (TACE) to cleave a membrane-proximal site in
pro-transforming growth factor- (proTGF). TGF is a
member of the epidermal growth factor (EGF) family
[36]. TGF is synthesized as a membrane bound pre-
cursor (proTGF) that is proteolytically cleaved to
release the EGF receptor binding ligand. Until recently,
the identities of the enzymes required for proteolytic
processing were unknown. A novel protease, tumor
necrosis factor- converting enzyme (TACE), was iden-
tified as being responsible for converting the mem-
brane-bound pro-TGF to its soluble form [16]. A
soluble epitope-tagged version of the ectodomain of
Figure 5. MALDI-MS/MS spectrum of standard biotinylated
peptide, affinity-bound to avidin beads, with a maximum of 216
fmol on target.
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proTGF, (proTGFecto) was created with a C-terminal
FLAG tag [37] (DYKDDDDKVV) [16]. Media concen-
trate solution from cells expressing this construct was
incubated with recombinant human TACE extracellular
domain for 4 h at 37 °C. Anti-FLAG M2 affinity resin
was subsequently added at the end of the incubation.
Immunoprecipitates were washed with 50 mM ammo-
nium bicarbonate and a small aliquot of the beads was
directly placed on the MALDI target.
Two peaks were observed in the MALDI-TOF/MS
spectrum, at m/z 2151.447 and 1811.119, as seen in
Figure 7a. The peak at 2151.447 matched the molecular
weight of a synthetic peptide with the sequence of the
expected product, VVAASQKKQDYKDDDDKVV with
cleavage occurring between Ala89 and Val90 (m/z
2151.350) [16]. Because the second product (at m/z
1811.119) was unexpected, its sequence was determined
by MALDI-MS/MS.
The product ion spectrum of m/z 1811.119 is shown
in Figure 7b. Although the overall intensity was low, a
series of b ions confirmed that the sequence of the
peptide was SQKKQDYKDDDDKVV, thus confirming
a second in vitro TACE cleavage site on proTGFecto,
between Ala94 and Ser95. Determination of the sequence
of the m/z 1811 product, therefore, allowed unambigu-
ous confirmation of the identity of an unexpected
proteolytic product, thereby providing firm indication
of a second, specific cleavage event.
Conclusions
In this study, we report a powerful method for isola-
tion, identification, and sequencing of peptides bound
to immobilized antibodies on affinity beads. Placing an
aliquot of the affinity beads directly on the MALDI
target eliminates sample loss that can occur with pep-
tide elution followed by nESI-MS/MS, which is the
usual “method of choice” for peptide sequencing. Di-
rect on-target analysis of affinity-bound analytes is also
a much more rapid approach than the previously-used
MALDI-MS based technique involving enzymatic lad-
der sequencing of affinity-bound peptides [6]. It should
Figure 6. MALDI-MS spectrum of standard TGF-FLAG peptide.
(a) was acquired with affinity beads irradiated by laser. (b) was
acquired with only matrix crystals irradiated. The matrix solvent
used for (a) and (b) was 45% ethanol, 45% water, and 10% formic
acid. (c) was acquired with only matrix crystals irradiated, with
methanol as the matrix solvent.
Figure 7. Direct MALDI-MS and MALDI-MS/MS spectra of the
FLAG-tagged TGFecto peptides cleaved by TACE. (a) is the
MALDI-MS spectrum. The peptide at m/z 1811.119 was unex-
pected. (b) is the MALDI-MS/MS spectrum of the ion at m/z
1811.199.
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also allow epitope mapping of proteins with unknown
or variable sequences, and should greatly simplify the
epitope mapping of polyclonal antibodies.
This new method, which provides sample enrich-
ment with minimal sample handling, has been demon-
strated for a variety of antibody beads commonly used
in protein purification studies, and has been used to
identify an unknown cleavage site on a FLAG-tagged
protein. All affinity techniques, including this method,
are vulnerable to non-specific binding. The ability to
obtain sequence information on the affinity-bound pep-
tides makes it easier to distinguish between specifically-
and non-specifically-bound peptides, especially when
the affinity tag is known, as it is in the FLAG peptide
example described here.
Nelson et al. [32–35], have described the use of
epitope-tagged proteins and peptides in direct BIAcore-
MALDI-MS analysis. The applications of the direct
MALDI MS/MS would be analogous, with the impor-
tant advantage that it would not rely on incomplete
cleavage of the protein and analysis by peptide mass
fingerprinting or enzymatic protein ladder sequencing
in order to identify the protein. Using MALDI-MS/MS,
a protein (or a family of homologous proteins) could be
identified from a single bound peptide.
In addition, this approach is also applicable to the
characterization of non-epitope tagged proteins. This
has been demonstrated for several proteins, including
cancer-related proteins like p53, and is currently being
used for the development of a mass spectrometric-
based protein chip [38] for rapid determination of
differential expression of targeted proteins.
The high mass accuracy of the QqTOF mass spec-
trometer is not affected by the direct MALDI analysis of
affinity-bound peptides beads. With this high mass
accuracy, commercially-available proteomics software
packages such as Mascot can identify a protein (or a
family of homologous proteins which contain the same
peptide) from the MS/MS spectrum of one of its
peptides, and can automatically localize the modifica-
tion to a specific amino acid within that peptide, even
when the peptide is affinity-tagged. Thus, the method is
well suited for molecular characterization of epitope-
containing peptides, and for protein chips.
Acknowledgments
This work was supported by a gift from an anonymous donor for
research targeted to Proteomics and Cystic Fibrosis, and by grant
CA85410 (to DCL) from the National Institutes of Health.
References
1. Suckau, D.; Kohl, J.; Karwath, G.; Schneider, K.; Casaretto, M.;
Bitter-Suermann, D.; Przybylski, M. Molecular Epitope Iden-
tification by Limited Proteolysis of an Immobilized Antigen–
Antibody Complex and Mass Spectrometric Peptide Mapping.
Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 9848–9852.
2. Kiselar, J. G.; Downard, K. M. Direct Identification of Protein
Epitopes by Mass Spectrometry without Immobilization of
Antibody and Isolation of Antibody–Peptide Complexes.
Anal. Chem. 1999, 71, 1792–1801.
3. Hart, S. R.; Waterfield, M. D.; Burlingame, A. L.; Cramer, R.
Factors Governing the Solubilization of Phosphopeptides Re-
tained on Ferric NTA IMAC Beads and Their Analysis by
MALDI TOFMS. J. Am. Soc. Mass Spectrom. 2002, 13, 1042–
1051.
4. Papac, D. I.; Hoyes, J.; Tomer, K. B. Direct Analysis of
Affinity-Bound Analytes by MALDI/TOF MS. Anal. Chem.
1994, 66, 2609–2613.
5. Gevaert, K.; Demol, H.; Puype, M.; Broekaert, D.; De Boeck, S.;
Houthaeve, T.; Vandekerckhove, J. Peptides Adsorbed on
Reverse-Phase Chromatographic Beads as Target for Femto-
mole Sequencing by Post-Source Decay Matrix-Assisted Laser
Desorption/Ionization-Reflectron Time-of-Flight Mass Spec-
trometry (MALDI-RETOF-MS). Electrophoresis 1997, 18, 2950–
2960.
6. Parker, C. E.; Tomer, K. B. MALDI/MS-Based Epitope Map-
ping of Antigens Bound to Immobilized Antibodies. Mol.
Biotechnol. 2002, 20, 49–62.
7. Qian, X.; Zhou, W.; Khaledi, M. G.; Tomer, K. B. Sequential
Cleavages of Peptides and Proteins Affinity-Bound to Immo-
bilized Metal Ion Beads by Matrix-Assisted Laser Desorption/
Ionization Mass Spectrometry. Anal. Biochem. 1999, 274, 174–
180.
8. Parker, C. E.; Tomer, K. B. Epitope Mapping by a Combination
of Epitope Excision and MALDI-MS. Methods Mol. Biol. 2000,
146, 185–201.
9. Zhao, Y.; Chait, B. T. Protein Epitope Mapping by Mass
Spectrometry. Anal. Chem. 1994, 66, 3723–3726.
10. Parker, C. E.; Papac, D. I.; Tomer, K. B. Monitoring Cleavage of
Fusion Proteins by Matrix-Assisted Laser Desorption/Ioniza-
tion Mass Spectrometry: Recombinant HIV-1IIIB p26. Anal.
Biochem. 1996, 239, 25–34.
11. Parker, C. E.; Papac, D. I.; Trojak, S. K.; Tomer, K. B. Epitope
Mapping by Mass Spectrometry: Determination of an Epitope
on HIV-1 IIIB p26 Recognized by a Monoclonal Antibody.
J. Immunol. 1996, 157, 198–206.
12. Loboda, A. V.; Krutchinsky, A. N.; Bromirski, M.; Ens, W.;
Standing, K. G. A Tandem Quadrupole/Time-of-Flight Mass
Spectrometer with a Matrix-Assisted Laser Desorption/Ion-
ization Source: Design and Performance. Rapid Commun. Mass
Spectrom. 2000, 14, 1047–1057.
13. Baldwin, M. A.; Medzihradszky, K. F.; Lock, C. M.; Fisher, B.;
Settineri, T. A.; Burlingame, A. L. Matrix-Assisted Laser De-
sorption/Ionization Coupled with Quadrupole/Orthogonal
Acceleration Time-of-Flight Mass Spectrometry for Protein
Discovery, Identification, and Structural Analysis. Anal. Chem.
2001, 73, 1707–1720.
14. Raska, C. S.; Parker, C. E.; Dominski, Z.; Marzluff, W. F.; Glish,
G. L.; Pope, R. M.; Borchers, C. H. Direct MALDI-MS/MS of
Phosphopeptides Affinity-Bound to IMAC Beads. Anal. Chem.
2002, 74, 3429–3433.
15. Wang, H.; Tseng, K.; Lebrilla, C. B. A General Method for
Producing Bioaffinity MALDI Probes. Anal. Chem. 1999, 71,
2014–2020.
16. Sunnarborg, S. W.; Hinkle, C. L.; Stevenson, M.; Russell, W. E.;
Raska, C. S.; Peschon, J. J.; Castner, B. J.; Gerhart, M. J.; Paxton,
R. J.; Black, R. A.; Lee, D. C. Tumor Necrosis Factor-
Converting Enzyme (TACE) Regulates Epidermal Growth
Factor Receptor Ligand Availability. J. Biol. Chem. 2002, 277,
12838–12845.
17. Doedens, J. R.; Black, R. A. Stimulation-Induced Down-Regu-
lation of Tumor Necrosis Factor- Converting Enzyme. J. Biol.
Chem. 2000, 275, 14598–14607.
18. Perkins, D. N.; Pappin, D. J.; Creasy, D. M.; Cottrell, J. S.
Probability-Based Protein Identification by Searching Se-
1084 RASKA ET AL. J Am Soc Mass Spectrom 2003, 14, 1076–1085
quence Databases Using Mass Spectrometry Data. Electro-
phoresis 1999, 20, 3551–3567.
19. Roepstorff, P.; Fohlman, J. Proposal for a Common Nomen-
clature for Sequence Ions in Mass Spectra of Peptides. Biomed.
Mass Spectrom. 1984, 11, 601.
20. Biemann, K. Contributions of Mass Spectrometry to Peptide
and Protein Structure. Biomed. Environ. Mass Spectrom. 1988,
16, 99–111.
21. Clauser, K. R.; Baker, P.; Burlingame, A. L. Role of Accurate
Mass Measurement (10 ppm) in Protein Identification Strat-
egies Employing MS or MS/MS and Database Searching. Anal.
Chem. 1999, 71, 2871–2882.
22. McLachlin, D. T.; Chait, B. T. Analysis of Phosphorylated
Proteins and Peptides by Mass Spectrometry. Curr. Op. Chem.
Bio. 2001, 5, 591–602.
23. Chait, B. T.; Wang, R.; Beavis, R. C.; Kent, S. B. H. Protein
Ladder Sequencing. Science 1993, 262, 89–92.
24. Jeyarajah, S.; Parker, C. E.; Sumner, M. T.; Tomer, K. B.
Matrix-Assisted Laser Desorption/Ionization Mass Spectro-
metry Mapping of Human Immunodeficiency Virus-gp120
Epitopes Recognized by a Limited Polyclonal Antibody. J. Am.
Soc. Mass Spectrom. 1998, 9, 157–165.
25. Hochleitner, E. O.; Borchers, C.; Parker, C.; Bienstock, R. J.;
Tomer, K. B. Characterization of a Discontinuous Epitope of
the Human Immunodeficiency Virus (HIV) Core Protein p24
by Epitope Excision and Differential Chemical Modification
Followed by Mass Spectrometric Peptide Mapping Analysis.
Protein Science 2000, 9, 487–496.
26. Hochleitner, E. O.; Gorny, M. K.; Zolla-Pazner, S.; Tomer, K. B.
Mass Spectrometric Characterization of a Discontinuous
Epitope of the HIV Envelope Protein HIV-gp120 Recognized
by the Human Monoclonal Antibody 1331A. J. Immunol. 2000,
164, 4156–4161.
27. Raska, C. S.; Parker, C. E.; Huang, C.; Han, J.; Glish, G. L.;
Pope, M.; Borchers, C. H. Pseudo-MS3 in a MALDI Orthogo-
nal Quadrupole Time-of-Flight Mass Spectrometer. J. Am. Soc.
Mass Spectrom. 2002, 13, 1034–1041.
28. Han, J.; Pope, M.; Borchers, C.; Graves, L. M. Mapping of
Protein Phosphorylation by Dual Enzyme Digestion and Ma-
trix-Assisted Laser Desorption/Ionization-Quadrupole Or-
thogonal Time-of-Flight Mass Spectrometry. Anal. Biochem.
2002, 310, 215–218.
29. Green, N. M. Avidin. Adv. Prot. Chem. 1975, 29, 85–133.
30. Kohanski, R.A.; Lane, M. D. Monovalent Avidin Afinity
Columns. Methods Enzymol. 1990, 184, (Avidin-Biotin Tech-
nol.) 194–200.
31. Piran, U.; Riordan, W. J. Dissociation Rate Constant of the
Biotin–Streptavidin Complex. J. Immunol. Methods 1990, 133,
141–143.
32. Krone, J. R.; Nelson, R. W.; Dogruel, D.; Williams, P.; Gran-
zow, R. BIA/MS: Interfacing Biomolecular Interaction Analy-
sis with Mass Spectrometry. Anal. Biochem. 1997, 244, 124–132.
33. Nelson, R. W.; Krone, J. R.; Dogruel, D.; Tubbs, K.; Granzow, R.;
Jansson, O. Interfacing Biomolecular Interaction Analysis with
Mass Spectrometry and the Use of Bioreactive Mass Spectrome-
ter Probe Tips in Protein Characterization. Techniques in Protein
Chemistry VIII. Proceedings of the Symposium of the 10th Protein
Society; San Jose, CA, August, 1996 (1997); pp 493–504.
34. Nelson, R. W.; Krone, J. R.; Jansson, O. Surface Plasmon
Resonance Biomolecular Interaction Analysis Mass Spectro-
metry. 1. Chip-Based Analysis. Anal. Chem. 1997, 69, 4363–
4368.
35. Nelson, R. W.; Jarvik, J. W.; Taillon, B. E.; Kemmons, K. A.
BIA/MS of Epitope-Tagged Peptides Directly from E. coli
Lysate: Multiplex Detection and Protein Identification at Low-
Femtomole to Subfemtomole Levels. Anal. Chem. 1999, 71,
2858–2865.
36. Lee, D. C.; Fenton, S. E.; Berkowitz, E. A.; Hissong, M. A.
Transforming Growth Factor-: Expression, Regulation, and
Biological Activities. Pharm. Res. 1995, 47, 51–85.
37. Einhauer, A.; Jungbauer, A. The FLAG Peptide, a Versatile
Fusion Tag for the Purification of Recombinant Proteins.
J. Biochem. Biophys. Methods 2001, 49, 455–465.
38. Borchers, C. H. (patent application filed on 12/02/2002); U.S.
Patent Application Pub. 2002.
1085J Am Soc Mass Spectrom 2003, 14, 1076–1085 ID OF EPITOPE PEPTIDES BY DIRECT MALDI-MS/MS
